SCHEMBL3056754

SCHEMBL3056754

CNCCc1ccccc1Br

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAAR1 Q96RJ0 9/20 1.00
ATM Q13315 1/20 0.50
HTR2A P28223 2/20 0.46
ALDH1A1 P00352 2/20 0.46
KDM4E B2RXH2 1/20 0.46
HTR1A P08908 1/20 0.46
HTT P42858 1/20 0.46
CARM1 Q86X55 1/20 0.44
PRMT6 Q96LA8 1/20 0.44
HRH3 Q9Y5N1 1/20 0.42
IDO1 P14902 2/20 0.42
LMNA P02545 1/20 0.41
ALOX15 P16050 1/20 0.41
CHRNB2 P17787 1/20 0.41
CHRNA7 P36544 1/20 0.41
CHRNA4 P43681 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
TSHR P16473 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6226223 0.88 TAAR1 (0.78) TAAR1ATMHTR2ACARM1PRMT6
SCHEMBL11024614 0.79 TAAR1 (0.66) TAAR1HTR2AIDO1LMNATSHR
SCHEMBL29351396 0.78 TAAR1 (0.71) TAAR1ALDH1A1IDO1LMNATSHR
SCHEMBL6738136 0.78 TAAR1 (0.71) TAAR1ALDH1A1IDO1LMNATSHR
SCHEMBL11023397 0.78 TAAR1 (0.63) TAAR1HTR2AALDH1A1IDO1LMNA
SCHEMBL419400 0.77 TAAR1 (0.63) TAAR1HTR2AALDH1A1KDM4EIDO1
SCHEMBL3057770 0.76 TAAR1 (0.61) TAAR1ATMHTR2AALDH1A1KDM4E
SCHEMBL3053777 0.76 TAAR1 (0.61) TAAR1ATMHTR2AALDH1A1KDM4E
SCHEMBL3062235 0.76 TAAR1 (0.61) TAAR1ATMHTR2AALDH1A1KDM4E
SCHEMBL29686650 0.75 MTNR1A (0.61) TAAR1KDM4ELMNAMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115677616-B Macrocyclic sulfonamide compound, preparation method and medical application thereof 中国药科大学 2024-10-18 CN disclosed
CN-116829532-A Substituted cyclohexane carboxamides, their preparation and their therapeutic use 赛诺菲 2023-09-29 CN disclosed
WO-2023078127-A1 MACROCYCLIC SULFONAMIDE COMPOUND, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF 中国药科大学 2023-05-11 WO disclosed
CN-115677616-A Macrocyclic sulfonamide compound, preparation method and medical application thereof 中国药科大学 2023-02-03 CN disclosed
CN-104903300-B COMT inhibitor 霍夫曼-拉罗奇有限公司 2018-04-17 CN disclosed
US-9656971-B2 COMT inhibitors HOFFMANN-LA ROCHE INC. (US) 2017-05-23 US disclosed
EP-2938600-B1 COMT INHIBITORS HOFFMANN LA ROCHE (CH) 2017-01-25 EP disclosed
US-20160002177-A1 COMT INHIBITORS HOFFMANN-LA ROCHE INC. (US) 2016-01-07 US disclosed
EP-2938600-A1 COMT INHIBITORS F. Hoffmann-La Roche AG (CH) 2015-11-04 EP disclosed
CN-104903300-A Comt inhibitors HOFFMANN LA ROCHE 2015-09-09 CN disclosed
WO-2014102233-A1 COMT INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2014-07-03 WO disclosed
US-8394979-B2 Process for preparing cycloplatinated platinum complexes, platinum complexes prepared by this process and the use thereof RHEINISCHE-WESTFALISCHE TECHNISCHE HOCHSCHULE AACHEN (DE) 2013-03-12 US disclosed
US-20100267977-A1 METHOD FOR PRODUCING CYCLOPLATINIZED PLATINUM COMPLEXES, PLATINUM COMPLEXES PRODUCED BY SAID METHOD, AND THE USE THEREOF RHEINISCHE-WESTFALISCHE TECHNISCHE HOCHSCHULE AACHEN (DE) 2010-10-21 US disclosed
US-20080004290-A1 Anti-Cancer Agents THE UNIVERSITY OF QUEENSLAND (AU) 2008-01-03 US disclosed
US-20080004290-A1 Anti-Cancer Agents THE UNIVERSITY OF QUEENSLAND (AU) 2008-01-03 US disclosed
WO-2002072547-A1 AMINATION PROCESS ADVANCED RESEARCH AND TECHNOLOGY INSTITUTE, INC. (US) 2002-09-19 WO disclosed
WO-2002070439-A2 AMINATION PROCESS JOHNSTON, JEFFREY, N. 2002-09-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160002177-A1 COMT INHIBITORS COMT, PNMT, SLC6A3 TAAR1 1584/4885ATM 3481/4885HTR2A 103/4885
US-20100267977-A1 METHOD FOR PRODUCING CYCLOPLATINIZED PLATINUM COMPLEXES, PLATINUM COMPLEXES PRODUCED BY SAID METHOD, AND THE USE THEREOF THPO, MCL1, PPOX TAAR1 4519/4885ATM 3588/4885HTR2A 4718/4885
US-20080004290-A1 Anti-Cancer Agents TP53, TOP2A, MCL1 TAAR1 4733/4885ATM 1519/4885HTR2A 4634/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.